Nilutamide
- Atc Codes:L02BB02
- CAS Codes:63612-50-0
- PHARMGKB ID:63612-50-0
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
France: Anandron; Greece: Anandron; Hungary: Anandron; Netherlands: Anandron; Poland: Anandron; Portugal: Anandron.
North America
Canada: Anandron; USA: Nilandron.
Latin America
Brazil: Anandron; Mexico: Anandron.
Drug combinations
Chemistry
Nilutamide: C~12~H~10~F~3~N~3~O~4~. Mw: 317.22. (1) 2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-; (2) 5,5-Dimethyl-3-(α,α,α-trifluoro-4-nitro-m-tolyl)hydantoin. CAS-63612-50-0 (1995).
Pharmacologic Category
Antineoplastic Agents; Endocrine Therapy; Antiandrogen. (ATC-Code: L02BB02).
Mechanism of action
Inhibits androgen uptake or inhibits binding of androgen in target tissues. Specifically blocks action of androgens by interacting with cytosolic androgen receptor F sites in target tissue.
Therapeutic use
Treatment of metastatic prostate cancer.
Pregnancy and lactiation implications
Not indicated for use in women.
Unlabeled use
Contraindications
Hypersensitivity to nilutamide or any component of the formulation. Severe hepatic impairment. Severe respiratory insufficiency.
Warnings and precautions
Hepatitis or marked increases in liver enzymes occurred in 1% of nilutamide patients. Rare cases of elevated hepatic enzymes followed by death reported. Interstitial pneumonitis reported in 2% of patients exposed to nilutamide. 13% to 57% of patients receiving nilutamide reported delay in adaptation to the dark, ranging from seconds to a few minutes (effect sometimes does not abate as drug treatment is continued).